A cost-benefit analysis of a population screening programme for neural tube defects
- 1 April 1983
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 3 (2) , 117-126
- https://doi.org/10.1002/pd.1970030207
Abstract
Population screening for neural tube defects is possible by measuring maternal serum alpha‐fetoprotein levels with appropriate follow‐up as required. British Columbia has approximately 39 000 births annually and the incidence of neural tube defects is 1–55 per 1000 births (0–94 per 1000 livebirths). Results from a cost‐benefit analysis suggest that the outlined screening programme would be cost‐beneficial for British Columbia. Other important factors essential to consider before instituting a population screening programme are discussed.Keywords
This publication has 20 references indexed in Scilit:
- A cost-benefit analysis of prenatal diagnosis for neural tube defects selectively offered to relatives of index casesAmerican Journal of Medical Genetics, 1982
- Maternal serum alpha-fetoprotein screening: A report of the Forsyth County ProjectAmerican Journal of Obstetrics and Gynecology, 1981
- Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects.BMJ, 1981
- Prenatal fetal karyotyping and maternal serum alpha-fetoprotein screening.BMJ, 1981
- A cost-benefit analysis of prenatal detection of down syndrome and neural tube defects in older mothersAmerican Journal of Medical Genetics, 1981
- Maternal serum alpha-fetoprotein screening: a cost-benefit analysis.American Journal of Public Health, 1979
- SIGNIFICANCE OF ELEVATED MID-TRIMESTER MATERNAL PLASMA-ALPHA-FETOPROTEIN VALUESThe Lancet, 1979
- Sib risks of anencephaly and spina bifida in British ColumbiaAmerican Journal of Medical Genetics, 1979
- AVOIDANCE OF ANENCEPHALIC AND SPINA BIFIDA BIRTHS BY MATERNAL SERUM-ALPHAFETOPROTEIN SCREENINGThe Lancet, 1978
- FETAL WASTAGE AS A RESULT OF AN ALPHA-FETOPROTEIN SCREENING PROGRAMMEThe Lancet, 1978